@article{Bornemann:2024:10.3389/fpsyt.2024.1320780,
author = {Bornemann, J and Close, JB and Ahmad, K and Barba, T and Godfrey, K and Macdonald, L and Erritzoe, D and Nutt, D and Carhart-Harris, R},
doi = {10.3389/fpsyt.2024.1320780},
journal = {Frontiers in Psychiatry},
title = {Study protocol for “Psilocybin in patients with fibromyalgia: brain biomarkers of action”},
url = {http://dx.doi.org/10.3389/fpsyt.2024.1320780},
volume = {15},
year = {2024}
}

Download

TY  - JOUR
AB  - Background: Chronic pain is a leading cause of disability worldwide. Fibromyalgia is a particularly debilitating form of widespread chronic pain. Fibromyalgia remains poorly understood, and treatment options are limited or moderately effective at best. Here, we present a protocol for a mechanistic study investigating the effects of psychedelic-assisted-therapy in a fibromyalgia population. The principal focus of this trial is the central mechanism(s) of psilocybin-therapy i.e., in the brain and on associated mental schemata, primarily captured by electroencephalography (EEG) recordings of the acute psychedelic state, plus pre and post Magnetic Resonance Imaging (MRI).Methods: Twenty participants with fibromyalgia will complete 8 study visits over 8 weeks. This will include two dosing sessions where participants will receive psilocybin at least once, with doses varying up to 25mg. Our primary outcomes are 1) Lempel-Ziv complexity (LZc) recorded acutely using EEG, and the 2) the (Brief Experiential Avoidance Questionnaire (BEAQ) measured at baseline and primary endpoint. Secondary outcomes will aim to capture broad aspects of the pain experience and related features through neuroimaging, self-report measures, behavioural paradigms, and qualitative interviews. Pain Symptomatology will be measured using the Brief Pain Inventory Interference Subscale (BPI-IS), physical and mental health-related function will be measured using the 36-Item Short Form Health Survey (SF-36). Further neurobiological investigations will include functional MRI (fMRI) and diffusion tensor imaging (changes from baseline to primary endpoint), and acute changes in pre- vs post-acute spontaneous brain activity – plus event-related potential functional plasticity markers, captured via EEG.Discussion: The results of this study will provide valuable insight into the brain mechanisms involved in the action of psilocybin-therapy for fibromyalgia with potential implications for the therapeutic actio
AU  - Bornemann,J
AU  - Close,JB
AU  - Ahmad,K
AU  - Barba,T
AU  - Godfrey,K
AU  - Macdonald,L
AU  - Erritzoe,D
AU  - Nutt,D
AU  - Carhart-Harris,R
DO  - 10.3389/fpsyt.2024.1320780
PY  - 2024///
SN  - 1664-0640
TI  - Study protocol for “Psilocybin in patients with fibromyalgia: brain biomarkers of action”
T2  - Frontiers in Psychiatry
UR  - http://dx.doi.org/10.3389/fpsyt.2024.1320780
UR  - http://hdl.handle.net/10044/1/112910
VL  - 15
ER  - 

Download